Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- cardiovascular -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (18)	1/27/2002 10:49:30 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 214

You are amazing. Thanks. Even I can see that chronic, small mol anti-18 would be much better than MI Mab. BTW, still haven't obtained a copy of the cardio/inflam review article but intend to soon. I hope I am smarter, and not just a few hours older, after I read it. More BTW, avan will have results in anti-C1 (but actually inhibit at c3 I hear) in cpb soon. Should be very interesting from efficacy point of view, though I am most interested in its safety results. Wilder